IL-6-induced DNMT1 activity mediates SOCS3 promoter hypermethylation in ulcerative colitis-related colorectal cancer

Carcinogenesis

Volumn 33, Issue 10, 2012, Pages 1889-1896

  Li, Yi ^a,b   Deuring, Jasper ^a,b   Peppelenbosch, Maikel P ^a,b   Kuipers, Ernst J ^a,b   de Haar, Colin ^a,b   van der Woude, C Janneke ^a,b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; DNA METHYLTRANSFERASE 1; INTERLEUKIN 6; STAT3 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 3;

ADULT; ARTICLE; CANCER CELL; CELL PROLIFERATION; CELL STIMULATION; CELL TRANSFORMATION; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; DNA METHYLATION; DOWN REGULATION; DYSPLASIA; ENZYME ACTIVITY; EPITHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; REGULATORY MECHANISM; TUMOR GENE; ULCERATIVE COLITIS;

CELL TRANSFORMATION, NEOPLASTIC; COLITIS, ULCERATIVE; COLON; COLORECTAL NEOPLASMS; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DNA METHYLATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERLEUKIN-6; INTESTINAL MUCOSA; MALE; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS;

EID: 84867322245     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgs214     Document Type: Article

References (26)

1. Cho, J.H. (2008) The genetics and immunopathogenesis of inflammatory bowel disease. Nat. Rev. Immunol., 8, 458-466.
2. Eaden, J.A. et al. (2001) The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut, 48, 526-535.
3. Eaden, J. (2004) Review article: colorectal carcinoma and inflammatory bowel disease. Aliment. Pharmacol. Ther., 20 (Suppl. 4), 24-30.
4. Sartor, R.B. (2006) Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis. Nat. Clin. Pract. Gastroenterol. Hepatol., 3, 390-407.
5. Schottelius, A.J. et al. (2006) Cytokines, NF-kappaB, microenvironment, intestinal inflammation and cancer. Cancer Treat. Res., 130, 67-87.
6. Grivennikov, S. et al. (2009) IL-6 and stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell, 15, 103-113.
7. Bollrath, J. et al. (2009) gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell, 15, 91-102.
8. Li, Y. et al. (2010) Disease-related expression of the IL6/STAT3/SOCS3 signalling pathway in ulcerative colitis and ulcerative colitis-related carcinogenesis. Gut, 59, 227-235.
9. Wehbe, H. et al. (2006) Interleukin-6 contributes to growth in cholangiocarcinoma cells by aberrant promoter methylation and gene expression. Cancer Res., 66, 10517-10524.
10. Braconi, C. et al. (2010) MicroRNA-dependent regulation of DNA methyltransferase-1 and tumor suppressor gene expression by interleukin-6 in human malignant cholangiocytes. Hepatology, 51, 881-890.
11. Foran, E. et al. (2010) Upregulation of DNA methyltransferase-mediated gene silencing, anchorage-independent growth, and migration of colon cancer cells by interleukin-6. Mol. Cancer Res., 8, 471-481.
12. Lennard-Jones, J.E. (1989) Classification of inflammatory bowel disease. Scand. J. Gastroenterol. Suppl., 170, 2-6; discussion 16-19.
13. Weber, A. et al. (2005) SOCS-3 is frequently methylated in head and neck squamous cell carcinoma and its precursor lesions and causes growth inhibition. Oncogene, 24, 6699-6708.
14. Wang, M. et al. (2007) Deficiency of TNFR1 protects myocardium through SOCS3 and IL-6 but not p38 MAPK or IL-1beta. Am. J. Physiol. Heart Circ. Physiol., 292, H1694-1699.
15. Yin, Y. et al. (2010) Blocking effects of siRNA on VEGF expression in human colorectal cancer cells. World J. Gastroenterol., 16, 1086-1092.
16. Zhu, Y.M. et al. (2007) Expression of human DNA methyltransferase 1 in colorectal cancer tissues and their corresponding distant normal tissues. Int. J. Colorectal Dis., 22, 661-666.
17. Kodach, L.L. et al. (2010) Statins augment the chemosensitivity of colorectal cancer cells inducing epigenetic reprogramming and reducing colorectal cancer cell 'stemness' via the bone morphogenetic protein pathway. Gut, 60, 1544-1553.
18. Kim, S. et al. (2009) Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature, 457, 102-106.
19. Neurath, M.F. et al. (2010) IL-6 signaling in autoimmunity, chronic inflammation and inflammation-associated cancer. Cytokine Growth Factor Rev., 22, 83-89.
20. Fantini, M.C. et al. (2008) Cytokines: from gut inflammation to colorectal cancer. Curr. Drug Targets, 9, 375-380.
21. Suzuki, A. et al. (2001) CIS3/SOCS3/SSI3 plays a negative regulatory role in STAT3 activation and intestinal inflammation. J. Exp. Med., 193, 471-481.
22. Bocklandt, S. et al. (2011) Epigenetic predictor of age. PLoS One, 6, e14821.
23. Liu, L. et al. (2005) Epigenetic alterations in neuroendocrine tumors: methylation of RAS-association domain family 1, isoform A and p16 genes are associated with metastasis. Mod. Pathol., 18, 1632-1640.
24. Schneider, M.R. et al. (2000) Interleukin-6 stimulates clonogenic growth of primary and metastatic human colon carcinoma cells. Cancer Lett., 151, 31-38.
25. Rigby, R.J. et al. (2007) Suppressor of cytokine signaling 3 (SOCS3) limits damage-induced crypt hyper-proliferation and inflammation-associated tumorigenesis in the colon. Oncogene, 26, 4833-4841.
26. Li, Y. et al. (2011) New insights into the role of STAT3 in IBD. Inflamm. Bowel Dis., 18, 1177-1183.